{
    "info": {
        "nct_id": "NCT05994235",
        "official_title": "A Phase II Trial of Tazemetostat Plus Mosunetuzumab in Untreated Follicular Lymphoma",
        "inclusion_criteria": "Inclusion Criteria\n\nPatients must meet the following criteria for study entry:\n\n* Signed Informed Consent Form\n* Age: 18 years at the time of signing the Informed Consent Form\n* Ability to comply with the study protocol\n* Willing to follow lifestyle considerations as defined in Section 4.4\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2\n* Histologically documented FL (Grades 1-3a):\n\n  * Fluorodeoxyglucose avid lymphoma (i.e., positron emission tomography (PET) positive lymphoma)\n  * At least 1 bi-dimensionally measurable nodal lesion (˃1.5 cm in its largest dimension by computed tomography (CT) scan), or at least 1 bi-dimensionally measurable extra-nodal lesion (˃1.0 cm in its largest dimension by CT scan)\n* Meet Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria to receive systemic therapy\n* Received no prior systemic lymphoma therapy (local radiotherapy is not considered systemic therapy)\n* Availability of a representative tumor specimen and the corresponding pathology report at the time of diagnosis for confirmation of the diagnosis of FL and for EZH2 mutation testing.\n* Adequate hematologic function defined as follows:\n\n  * Hemoglobin >= 8.0 g/dL\n  * ANC >=1.0 x 10/L\n  * Platelet count >=75x10/L\n* Adequate renal and hepatic function as defined as follows:\n\n  * Measured or estimated creatinine clearance >=30 mL/min by institutional standard method\n  * AST or ALT <= 2.5 x the upper limit of normal (ULN)\n  * Serum total bilirubin <=1.5xULN (or <=3 x ULN for patients with Gilbert syndrome)\n\nPatients who meet any of the following criteria will be excluded from study entry:\n\n* Inability to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat\n* Grade 3b FL\n* History of transformation of indolent disease to diffuse large B cell lymphoma\n* Any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN)\n* Any prior history of T-LBL/T-ALL\n* Active or history of CNS lymphoma or leptomeningeal infiltration\n* Prior standard or investigational systemic anti-cancer therapy for lymphoma. Patients who have received prior XRT will not be excluded\n* Treatment with systemic immunosuppressive medications, including, but not limited to, prednisone (20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1\n\n  * The use of inhaled corticosteroids is permitted\n  * The use of mineralocorticoids for the management of orthostatic hypotension is permitted\n  * Dexamethasone for nausea, B symptoms, or symptomatic or bulky disease is permitted with a maximum dose of 40 mg x5 days or equivalent\n* History of solid organ transplantation\n* Contraindication to tocilizumab\n* History of severe allergic or anaphylactic reaction to humanized, chimeric or murine monoclonal antibodies (MAbs)\n* Known hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the mosunetuzumab or tazemetostat.\n* Known active bacterial, viral, fungal, or other infection, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1\n* Known or suspected chronic active Epstein-Barr virus (EBV) infection\n* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)\n* Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis, as determined by the principal investigator\n* Active Hepatitis B or Hepatitis C infection Note: Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation. Patients who are positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR to be eligible for study participation\n* HIV positive with CD4 count <200 and not currently taking antiretroviral therapy\n* History of progressive multifocal leukoencephalopathy (PML)\n* Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study\n\n  * Patients must not receive live, attenuated vaccines (e.g., FluMist) while receiving study treatment or after the last dose until B-cell recovery to the normal ranges.\n  * Inactivated influenza vaccination should be given during the influenza season only\n* Other malignancy that could affect compliance with the protocol or interpretation of results, with the exception of the following:\n\n  * Any of the following malignancies previously curatively treated: carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal, or squamous cell skin cancer\n  * Stage I melanoma, - Low-grade, early-stage localized prostate cancer\n  * Any other previously treated malignancy that has been in remission without treatment for >= 2 years prior to enrollment\n* Active autoimmune disease requiring treatment\n* History of autoimmune disease, including, but not limited to: myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis\n\n  * Patients with a remote history of, or well-controlled autoimmune disease, with a treatment free interval from immunosuppressive therapy for 12 months may be eligible to enroll if judged to be safe by the investigator\n  * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone are eligible Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study\n  * Patients with a history of disease-related immune thrombocytopenic purpura, or autoimmune hemolytic anemia may be eligible\n* Prior allogeneic stem cell transplant (SCT)\n* Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)\n* Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study\n* Active CNS disease or underlying neurologic disease such as stroke or intracranial hemorrhage within 3 months prior to enrollment, history of seizure disorder, or history of neurogenerative disease\n* History of pneumonitis or interstitial lung disease\n* A positive SARS-CoV-2 test within 7 days of C1D1\n* Pregnant or lactating or intending to become pregnant during the study\n\n  * Women of childbearing potential (WOCBP) must have 2 negative serum pregnancy test results (minimum sensitivity, 25 mIU/mL) prior to initiating therapy: at 10-14 days prior to Day 1 of Cycle 1 and within 24 hours prior to Day 1 of Cycle 1.\n  * WOCBP are defined as any person with a uterus who has had a menstrual period in the last 12 months, unless surgically sterile (i.e. from hysterectomy or bilateral oophorectomy)\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Any prior history of T-LBL/T-ALL",
            "criterions": [
                {
                    "exact_snippets": "Any prior history of T-LBL/T-ALL",
                    "criterion": "prior history of T-LBL/T-ALL",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active bacterial, viral, fungal, or other infection, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1",
            "criterions": [
                {
                    "exact_snippets": "Known active bacterial, viral, fungal, or other infection",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1",
                    "criterion": "major episode of infection requiring IV antibiotics",
                    "requirements": [
                        {
                            "requirement_type": "time since last episode",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "IV antibiotics"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "History of solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Contraindication to tocilizumab",
            "criterions": [
                {
                    "exact_snippets": "Contraindication to tocilizumab",
                    "criterion": "tocilizumab contraindication",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate renal and hepatic function as defined as follows:",
            "criterions": [
                {
                    "exact_snippets": "Adequate renal ... function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or lactating or intending to become pregnant during the study",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intending to become pregnant during the study",
                    "criterion": "intention to become pregnant during the study",
                    "requirements": [
                        {
                            "requirement_type": "intention",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis, as determined by the principal investigator",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant history of liver disease",
                    "criterion": "history of liver disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including viral or other hepatitis",
                    "criterion": "history of hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including ... cirrhosis",
                    "criterion": "history of cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by the principal investigator",
                    "criterion": "principal investigator determination",
                    "requirements": [
                        {
                            "requirement_type": "determination",
                            "expected_value": "principal investigator"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results",
            "criterions": [
                {
                    "exact_snippets": "Any serious medical condition ... precludes the patient's safe participation in and completion of the study",
                    "criterion": "serious medical condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "abnormality in clinical laboratory tests ... precludes the patient's safe participation in and completion of the study",
                    "criterion": "abnormality in clinical laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any serious medical condition or abnormality in clinical laboratory tests ... which could affect compliance with the protocol or interpretation of results",
                    "criterion": "serious medical condition or abnormality in clinical laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "potential to affect compliance or interpretation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active Hepatitis B or Hepatitis C infection Note: Patients who are hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR) to be eligible for study participation. Patients who are positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR to be eligible for study participation",
            "criterions": [
                {
                    "exact_snippets": "Active Hepatitis B or Hepatitis C infection",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Active Hepatitis B or Hepatitis C infection",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) positive, must be negative for hepatitis B virus (HBV) polymerase chain reaction (PCR)",
                    "criterion": "hepatitis B virus (HBV) PCR",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "positive for hepatitis C virus (HCV) antibody must be negative for HCV by PCR",
                    "criterion": "hepatitis C virus (HCV) PCR",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to comply with the study protocol",
            "criterions": [
                {
                    "exact_snippets": "Ability to comply with the study protocol",
                    "criterion": "ability to comply with study protocol",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematologic function defined as follows:",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematologic function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The use of inhaled corticosteroids is permitted",
            "criterions": [
                {
                    "exact_snippets": "The use of inhaled corticosteroids is permitted",
                    "criterion": "inhaled corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not receive live, attenuated vaccines (e.g., FluMist) while receiving study treatment or after the last dose until B-cell recovery to the normal ranges.",
            "criterions": [
                {
                    "exact_snippets": "Patients must not receive live, attenuated vaccines (e.g., FluMist) while receiving study treatment or after the last dose until B-cell recovery to the normal ranges.",
                    "criterion": "receipt of live, attenuated vaccines",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": [
                                "while receiving study treatment",
                                "after the last dose until B-cell recovery to the normal ranges"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any of the following malignancies previously curatively treated: carcinoma in situ of the cervix, good-prognosis ductal carcinoma in situ of the breast, basal, or squamous cell skin cancer",
            "criterions": [
                {
                    "exact_snippets": "carcinoma in situ of the cervix",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "history of curative treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "good-prognosis ductal carcinoma in situ of the breast",
                    "criterion": "ductal carcinoma in situ of the breast",
                    "requirements": [
                        {
                            "requirement_type": "prognosis",
                            "expected_value": "good"
                        },
                        {
                            "requirement_type": "history of curative treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "basal ... cell skin cancer",
                    "criterion": "basal cell skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of curative treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "squamous cell skin cancer",
                    "criterion": "squamous cell skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of curative treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fluorodeoxyglucose avid lymphoma (i.e., positron emission tomography (PET) positive lymphoma)",
            "criterions": [
                {
                    "exact_snippets": "Fluorodeoxyglucose avid lymphoma (i.e., positron emission tomography (PET) positive lymphoma)",
                    "criterion": "lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "fluorodeoxyglucose avidity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "positron emission tomography (PET) positivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Availability of a representative tumor specimen and the corresponding pathology report at the time of diagnosis for confirmation of the diagnosis of FL and for EZH2 mutation testing.",
            "criterions": [
                {
                    "exact_snippets": "Availability of a representative tumor specimen",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "representativeness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "the corresponding pathology report at the time of diagnosis",
                    "criterion": "pathology report at the time of diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for confirmation of the diagnosis of FL",
                    "criterion": "diagnosis of FL",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for EZH2 mutation testing",
                    "criterion": "EZH2 mutation testing",
                    "requirements": [
                        {
                            "requirement_type": "suitability for testing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active or history of CNS lymphoma or leptomeningeal infiltration",
            "criterions": [
                {
                    "exact_snippets": "Active or history of CNS lymphoma",
                    "criterion": "CNS lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "activity or history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal infiltration",
                    "criterion": "leptomeningeal infiltration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a remote history of, or well-controlled autoimmune disease, with a treatment free interval from immunosuppressive therapy for 12 months may be eligible to enroll if judged to be safe by the investigator",
            "criterions": [
                {
                    "exact_snippets": "remote history of, or well-controlled autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": [
                                "remote",
                                "well-controlled"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment free interval from immunosuppressive therapy for 12 months",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment free interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "may be eligible to enroll if judged to be safe by the investigator",
                    "criterion": "investigator judgment of safety",
                    "requirements": [
                        {
                            "requirement_type": "judged safe",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received no prior systemic lymphoma therapy (local radiotherapy is not considered systemic therapy)",
            "criterions": [
                {
                    "exact_snippets": "Received no prior systemic lymphoma therapy",
                    "criterion": "prior systemic lymphoma therapy",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "local radiotherapy is not considered systemic therapy",
                    "criterion": "local radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "exclusion from systemic therapy definition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >=75x10/L",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >=75x10/L",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75,
                                "unit": "x10/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected chronic active Epstein-Barr virus (EBV) infection",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected chronic active Epstein-Barr virus (EBV) infection",
                    "criterion": "chronic active Epstein-Barr virus (EBV) infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnostic certainty",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1",
                                "2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with systemic immunosuppressive medications, including, but not limited to, prednisone (20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic immunosuppressive medications, including, but not limited to, prednisone (20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1",
                    "criterion": "treatment with systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to Day 1 of Cycle 1"
                            }
                        },
                        {
                            "requirement_type": "medication_list",
                            "expected_value": [
                                "prednisone",
                                "azathioprine",
                                "methotrexate",
                                "thalidomide",
                                "anti-tumor necrosis factor agents"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other previously treated malignancy that has been in remission without treatment for >= 2 years prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Any other previously treated malignancy that has been in remission without treatment for >= 2 years prior to enrollment",
                    "criterion": "previously treated malignancy",
                    "requirements": [
                        {
                            "requirement_type": "remission duration without treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* WOCBP are defined as any person with a uterus who has had a menstrual period in the last 12 months, unless surgically sterile (i.e. from hysterectomy or bilateral oophorectomy)",
            "criterions": [
                {
                    "exact_snippets": "person with a uterus",
                    "criterion": "uterus presence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "had a menstrual period in the last 12 months",
                    "criterion": "menstrual period recency",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless surgically sterile (i.e. from hysterectomy or bilateral oophorectomy)",
                    "criterion": "surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "sterility",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sterilization method",
                            "expected_value": [
                                "hysterectomy",
                                "bilateral oophorectomy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum total bilirubin <=1.5xULN (or <=3 x ULN for patients with Gilbert syndrome)",
            "criterions": [
                {
                    "exact_snippets": "Serum total bilirubin <=1.5xULN (or <=3 x ULN for patients with Gilbert syndrome)",
                    "criterion": "serum total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "xULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "<=3 x ULN for patients with Gilbert syndrome",
                    "criterion": "serum total bilirubin in patients with Gilbert syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "xULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)",
            "criterions": [
                {
                    "exact_snippets": "Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)",
                    "criterion": "hemophagocytic lymphohistiocytosis (HLH)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: 18 years at the time of signing the Informed Consent Form",
            "criterions": [
                {
                    "exact_snippets": "Age: 18 years at the time of signing the Informed Consent Form",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other malignancy that could affect compliance with the protocol or interpretation of results, with the exception of the following:",
            "criterions": [
                {
                    "exact_snippets": "Other malignancy that could affect compliance with the protocol or interpretation of results",
                    "criterion": "other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "potential to affect compliance or interpretation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The use of mineralocorticoids for the management of orthostatic hypotension is permitted",
            "criterions": [
                {
                    "exact_snippets": "The use of mineralocorticoids for the management of orthostatic hypotension is permitted",
                    "criterion": "mineralocorticoid use",
                    "requirements": [
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "management of orthostatic hypotension"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to biopharmaceuticals produced in CHO cells or any component of the mosunetuzumab or tazemetostat.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to biopharmaceuticals produced in CHO cells",
                    "criterion": "hypersensitivity to biopharmaceuticals produced in CHO cells",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... any component of the mosunetuzumab",
                    "criterion": "hypersensitivity to any component of mosunetuzumab",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known hypersensitivity to ... any component of the ... tazemetostat",
                    "criterion": "hypersensitivity to any component of tazemetostat",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone are eligible Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study",
            "criterions": [
                {
                    "exact_snippets": "history of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone",
                    "criterion": "autoimmune-related hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "thyroid-replacement hormone"
                        },
                        {
                            "requirement_type": "treatment stability",
                            "expected_value": "stable dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "controlled Type 1 diabetes mellitus who are on an insulin regimen",
                    "criterion": "Type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "insulin regimen"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically documented FL (Grades 1-3a):",
            "criterions": [
                {
                    "exact_snippets": "Histologically documented FL (Grades 1-3a)",
                    "criterion": "follicular lymphoma (FL)",
                    "requirements": [
                        {
                            "requirement_type": "histological documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": ""
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "grade subtype exclusion",
                            "expected_value": "3a only (not 3b)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A positive SARS-CoV-2 test within 7 days of C1D1",
            "criterions": [
                {
                    "exact_snippets": "A positive SARS-CoV-2 test",
                    "criterion": "SARS-CoV-2 test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "within 7 days of C1D1",
                    "criterion": "time from SARS-CoV-2 test to C1D1",
                    "requirements": [
                        {
                            "requirement_type": "interval",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN)",
            "criterions": [
                {
                    "exact_snippets": "Any prior history of myeloid malignancies",
                    "criterion": "myeloid malignancies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myelodysplastic syndrome (MDS)",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute myeloid leukemia (AML)",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myeloproliferative neoplasm (MPN)",
                    "criterion": "myeloproliferative neoplasm (MPN)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study",
            "criterions": [
                {
                    "exact_snippets": "Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment",
                    "criterion": "live attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration before first dose",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation that such a live attenuated vaccine will be required during the study",
                    "criterion": "anticipated need for live attenuated vaccine during study",
                    "requirements": [
                        {
                            "requirement_type": "anticipated requirement during study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of transformation of indolent disease to diffuse large B cell lymphoma",
            "criterions": [
                {
                    "exact_snippets": "History of transformation of indolent disease to diffuse large B cell lymphoma",
                    "criterion": "transformation of indolent disease to diffuse large B cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior allogeneic stem cell transplant (SCT)",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic stem cell transplant (SCT)",
                    "criterion": "allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior standard or investigational systemic anti-cancer therapy for lymphoma. Patients who have received prior XRT will not be excluded",
            "criterions": [
                {
                    "exact_snippets": "Prior standard or investigational systemic anti-cancer therapy for lymphoma",
                    "criterion": "prior systemic anti-cancer therapy for lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of autoimmune disease, including, but not limited to: myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myocarditis",
                    "criterion": "myocarditis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myasthenia gravis",
                    "criterion": "myasthenia gravis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myositis",
                    "criterion": "myositis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune hepatitis",
                    "criterion": "autoimmune hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic lupus erythematosus",
                    "criterion": "systemic lupus erythematosus",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rheumatoid arthritis",
                    "criterion": "rheumatoid arthritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vascular thrombosis associated with antiphospholipid syndrome",
                    "criterion": "vascular thrombosis associated with antiphospholipid syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wegener's granulomatosis",
                    "criterion": "Wegener's granulomatosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Sjögren's syndrome",
                    "criterion": "Sjögren's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Guillain-Barré syndrome",
                    "criterion": "Guillain-Barré syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple sclerosis",
                    "criterion": "multiple sclerosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vasculitis",
                    "criterion": "vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "glomerulonephritis",
                    "criterion": "glomerulonephritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study",
            "criterions": [
                {
                    "exact_snippets": "Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1",
                    "criterion": "major surgical procedure (other than for diagnosis)",
                    "requirements": [
                        {
                            "requirement_type": "timing (relative to Day 1 of Cycle 1)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipation of a major surgical procedure during the course of the study",
                    "criterion": "anticipated major surgical procedure",
                    "requirements": [
                        {
                            "requirement_type": "timing (relative to study)",
                            "expected_value": "during the course of the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results",
                    "criterion": "significant, uncontrolled concomitant disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina)",
                    "criterion": "significant cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association Class III or IV cardiac disease",
                    "criterion": "New York Heart Association cardiac disease class",
                    "requirements": [
                        {
                            "requirement_type": "class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "NYHA class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within the previous 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable arrhythmia",
                    "criterion": "unstable arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)",
                    "criterion": "significant pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "obstructive pulmonary disease",
                    "criterion": "obstructive pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "history of bronchospasm",
                    "criterion": "history of bronchospasm",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Grade 3b FL",
            "criterions": [
                {
                    "exact_snippets": "Grade 3b FL",
                    "criterion": "follicular lymphoma (FL)",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "3b"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measured or estimated creatinine clearance >=30 mL/min by institutional standard method",
            "criterions": [
                {
                    "exact_snippets": "Measured or estimated creatinine clearance >=30 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "by institutional standard method",
                    "criterion": "creatinine clearance measurement method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "institutional standard method"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stage I melanoma, - Low-grade, early-stage localized prostate cancer",
            "criterions": [
                {
                    "exact_snippets": "Stage I melanoma",
                    "criterion": "melanoma",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "I"
                        }
                    ]
                },
                {
                    "exact_snippets": "Low-grade, early-stage localized prostate cancer",
                    "criterion": "prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": "low-grade"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "early-stage"
                        },
                        {
                            "requirement_type": "localization",
                            "expected_value": "localized"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Meet Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria to receive systemic therapy",
            "criterions": [
                {
                    "exact_snippets": "Meet Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria to receive systemic therapy",
                    "criterion": "GELF criteria for systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting) that might impair the bioavailability of tazemetostat",
            "criterions": [
                {
                    "exact_snippets": "Inability to take oral medication",
                    "criterion": "ability to take oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "malabsorption syndrome",
                    "criterion": "malabsorption syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any other uncontrolled gastrointestinal condition (eg, nausea, diarrhea, vomiting)",
                    "criterion": "uncontrolled gastrointestinal condition",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe allergic or anaphylactic reaction to humanized, chimeric or murine monoclonal antibodies (MAbs)",
            "criterions": [
                {
                    "exact_snippets": "History of severe allergic or anaphylactic reaction to humanized, chimeric or murine monoclonal antibodies (MAbs)",
                    "criterion": "allergic or anaphylactic reaction to monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "antibody_type",
                            "expected_value": [
                                "humanized",
                                "chimeric",
                                "murine"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring treatment",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring treatment",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 8.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 8.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed Informed Consent Form",
            "criterions": [
                {
                    "exact_snippets": "Signed Informed Consent Form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of pneumonitis or interstitial lung disease",
            "criterions": [
                {
                    "exact_snippets": "History of pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AST or ALT <= 2.5 x the upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "AST ... <= 2.5 x the upper limit of normal (ULN)",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT <= 2.5 x the upper limit of normal (ULN)",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* HIV positive with CD4 count <200 and not currently taking antiretroviral therapy",
            "criterions": [
                {
                    "exact_snippets": "HIV positive",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CD4 count <200",
                    "criterion": "CD4 count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 200,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not currently taking antiretroviral therapy",
                    "criterion": "antiretroviral therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of progressive multifocal leukoencephalopathy (PML)",
            "criterions": [
                {
                    "exact_snippets": "History of progressive multifocal leukoencephalopathy (PML)",
                    "criterion": "progressive multifocal leukoencephalopathy (PML)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Willing to follow lifestyle considerations as defined in Section 4.4",
            "criterions": [
                {
                    "exact_snippets": "Willing to follow lifestyle considerations as defined in Section 4.4",
                    "criterion": "lifestyle considerations (as defined in Section 4.4)",
                    "requirements": [
                        {
                            "requirement_type": "willingness to follow",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active CNS disease or underlying neurologic disease such as stroke or intracranial hemorrhage within 3 months prior to enrollment, history of seizure disorder, or history of neurogenerative disease",
            "criterions": [
                {
                    "exact_snippets": "Active CNS disease",
                    "criterion": "CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "underlying neurologic disease such as stroke or intracranial hemorrhage within 3 months prior to enrollment",
                    "criterion": "neurologic disease (stroke or intracranial hemorrhage)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months prior to enrollment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of seizure disorder",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of neurogenerative disease",
                    "criterion": "neurodegenerative disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ANC >=1.0 x 10/L",
            "criterions": [
                {
                    "exact_snippets": "ANC >=1.0 x 10/L",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.0,
                                "unit": "x 10/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of disease-related immune thrombocytopenic purpura, or autoimmune hemolytic anemia may be eligible",
            "criterions": [
                {
                    "exact_snippets": "history of disease-related immune thrombocytopenic purpura",
                    "criterion": "immune thrombocytopenic purpura",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease-related",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of ... autoimmune hemolytic anemia",
                    "criterion": "autoimmune hemolytic anemia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Dexamethasone for nausea, B symptoms, or symptomatic or bulky disease is permitted with a maximum dose of 40 mg x5 days or equivalent",
            "criterions": [
                {
                    "exact_snippets": "Dexamethasone for nausea, B symptoms, or symptomatic or bulky disease is permitted",
                    "criterion": "dexamethasone use",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": [
                                "nausea",
                                "B symptoms",
                                "symptomatic or bulky disease"
                            ]
                        },
                        {
                            "requirement_type": "permitted",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum dose of 40 mg x5 days or equivalent",
                    "criterion": "dexamethasone dose",
                    "requirements": [
                        {
                            "requirement_type": "maximum dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 40,
                                "unit": "mg"
                            }
                        },
                        {
                            "requirement_type": "maximum duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "equivalent dosing",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inactivated influenza vaccination should be given during the influenza season only",
            "criterions": [
                {
                    "exact_snippets": "Inactivated influenza vaccination should be given during the influenza season only",
                    "criterion": "inactivated influenza vaccination",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the influenza season only"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP) must have 2 negative serum pregnancy test results (minimum sensitivity, 25 mIU/mL) prior to initiating therapy: at 10-14 days prior to Day 1 of Cycle 1 and within 24 hours prior to Day 1 of Cycle 1.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have 2 negative serum pregnancy test results (minimum sensitivity, 25 mIU/mL) prior to initiating therapy",
                    "criterion": "serum pregnancy test results",
                    "requirements": [
                        {
                            "requirement_type": "number of tests",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "tests"
                            }
                        },
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "test type",
                            "expected_value": "serum pregnancy test"
                        },
                        {
                            "requirement_type": "minimum sensitivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 25,
                                "unit": "mIU/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at 10-14 days prior to Day 1 of Cycle 1 and within 24 hours prior to Day 1 of Cycle 1",
                    "criterion": "timing of serum pregnancy tests",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "10-14 days prior to Day 1 of Cycle 1",
                                "within 24 hours prior to Day 1 of Cycle 1"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Patients must meet the following criteria for study entry:",
            "criterions": []
        },
        {
            "line": "* At least 1 bi-dimensionally measurable nodal lesion (˃1.5 cm in its largest dimension by computed tomography (CT) scan), or at least 1 bi-dimensionally measurable extra-nodal lesion (˃1.0 cm in its largest dimension by CT scan)",
            "criterions": [
                {
                    "exact_snippets": "at least 1 bi-dimensionally measurable nodal lesion (˃1.5 cm in its largest dimension by computed tomography (CT) scan)",
                    "criterion": "nodal lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": "bi-dimensionally measurable"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "computed tomography (CT) scan"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 bi-dimensionally measurable extra-nodal lesion (˃1.0 cm in its largest dimension by CT scan)",
                    "criterion": "extra-nodal lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": "bi-dimensionally measurable"
                        },
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "CT scan"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "Patients who meet any of the following criteria will be excluded from study entry:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}